Small-molecule BRAF and MEK1/2 inhibitors (RAFi and MEKi) are now approved and used in the clinic to treat BRAF-mutant melanoma [11,12] and BRAF-mutant colorectal cancer [13]. This evidence concerns the gene BRAF and colorectal cancer.